Beth Hecht Sells 40,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Xeris Biopharma Trading Up 7.0 %

Shares of XERS opened at $5.81 on Friday. The firm has a market cap of $894.39 million, a P/E ratio of -12.91 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.69 and a 12-month high of $5.92. The company’s 50-day moving average price is $3.88 and its 200 day moving average price is $3.41.

Wall Street Analyst Weigh In

Several research firms have recently commented on XERS. Leerink Partners lifted their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, March 7th. Craig Hallum lifted their price target on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Piper Sandler reiterated a “neutral” rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $5.92.

Institutional Trading of Xeris Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in Xeris Biopharma by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after buying an additional 2,954 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Xeris Biopharma by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock worth $273,000 after purchasing an additional 3,447 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in Xeris Biopharma by 31.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company’s stock worth $55,000 after purchasing an additional 3,847 shares during the period. GPS Wealth Strategies Group LLC increased its stake in Xeris Biopharma by 6.2% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock worth $227,000 after purchasing an additional 3,900 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after purchasing an additional 5,500 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.